Summary
41 / 100 · Bulios Score
What speaks for it
- Revenue grew by 18% a year over the last 3 years.
- The price moves less than the market (beta 0.20).
What to watch
- The share price is above the Bulios Fair Price.
- Earnings per share fell by 13% a year over the last 3 years.
- It reports a profit, yet spends more cash than it brings in.
- Operating profit covers the interest on its debt only 2.2 times.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 41.5 IDR for 1 IDR of yearly profit. Over the last five years it was 156.9 IDR on average.
Valuation in detailIs it growing?
SlowlyRevenue (IDR)
Diluted EPS (IDR)
Revenue grew by 19% a year over 5 years. Over the last 3 years it grew by 18% a year. Earnings per share fell by 13% a year over the last 3 years.
Growth in detailDoes it make money?
PoorlyWhere 100 IDR of revenue goes
- Cost of sales 74 IDR
- Sales and administration 17 IDR
- Taxes and other 5.8 IDR
- Net profit 3.2 IDR
Net profit, industry median (Medical - Care Facilities) 6.7 IDR
Out of every 100 IDR of revenue, 3.2 IDR is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, at risk- Yield
- 0.25%
- Paid out of profit
- 10%
You receive 2.42 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail